STOCK TITAN
  1. Home
  2. News
  3. TXG

10x Genomics Inc - TXG STOCK NEWS

Welcome to our dedicated news page for 10x Genomics (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10x Genomics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 10x Genomics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 10x Genomics's position in the market.

News
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News
10x Genomics Launches Xenium Catalyst Network
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) launches Xenium Catalyst Network with 4 founding members to accelerate access to proof-of-concept data for prospective customers worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
none
-
News
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) published a study in Nature Communications using its industry-leading platforms to analyze human breast tumor microenvironments, showcasing the power of integrating findings and the value of spatial profiling techniques.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
News
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
Rhea-AI Summary
10x Genomics, Inc. (Nasdaq: TXG) announced that the Xenium In Situ platform demonstrated higher quality transcript counts per gene at higher specificity for 22 FFPE tissues compared to NanoString's CosMx and Vizgen's MERSCOPE in a new comparison study. Xenium showed higher sensitivity, on-target calls, and lower false discovery rate, as well as better correlation with reference RNA sequencing data. The platform also accurately measured low-expressing genes, exhibited a distinct tissue marker expression pattern, and performed well at distinguishing cells of distinct lineage and identifying all known cell types from breast and lung tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
-
News
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
Rhea-AI Summary
10x Genomics, Inc. (TXG) collaborates with NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a comprehensive single cell atlas of the human brain. The collaboration aims to further neuroscience research by profiling the epigenome and whole transcriptome across millions of individual cells from diverse brain samples. The goal is to provide a detailed genetic map of the damage caused in neurodegenerative disorders, facilitating the development of new treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
none
-
News
Curio Bioscience Responds to Lawsuit
Rhea-AI Summary
Curio Bioscience (CURIO) is a leading innovator in the life sciences industry, offering high-precision tools. Their Curio Seeker product enables whole transcriptome, spatial mapping of fresh frozen tissue at industry-leading resolution. The company is facing litigation from 10x Genomics (TXG) but is confident in their defense against patent infringement allegations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
News
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Rhea-AI Summary
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString, Awarded Over $31 Million in Damages: A jury in the U.S. District Court for the District of Delaware unanimously ruled in favor of 10x Genomics in the patent infringement suit against NanoString, awarding over $31 million in damages for willful infringement of seven patents. The ruling is the third against NanoString in six months, confirming serial infringement of 10x patents. Post-trial, 10x intends to seek ongoing royalties, treble damages, attorney's fees, a permanent injunction, and pre- and post-judgment interest. 10x's Chief Legal Officer emphasized the importance of protecting patents and thanked the jury for recognizing 10x's innovation. The ruling is based on extensive evidence, including testimony from key figures. This case is part of a larger legal battle, with another suit pending against NanoString in the U.S. District Court for the District of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
Rhea-AI Summary
OWKIN and 10x Genomics have entered into an agreement to incorporate 10x Genomics' spatial omics and single-cell technologies into the MOSAIC project. MOSAIC is a $50 million project that utilizes spatial omics technologies to map tumor structures at single-cell resolution. With the addition of 10x Genomics' Visium technology and Chromium portfolio, MOSAIC aims to unlock transformative discoveries in cancer research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News
10x Genomics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
10x Genomics reports Q3 2023 financial results with revenue of $153.6 million, a 17% increase YoY. Gross margin was 62%, operating expenses increased by 35%, and operating loss was $94.8 million. Net loss was $93.0 million. Cash and cash equivalents were $356.9 million. Full year 2023 revenue guidance raised to $610 million to $625 million, representing 18% to 21% growth over 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.73%
Tags
earnings
News
10x Genomics to Present at the Stephens 25th Annual Conference
Rhea-AI Summary
10x Genomics, Inc. will participate in a fireside chat at the Stephens 25th Annual Conference on November 14, 2023. The live webcast can be accessed on the company's website and will be available for replay for 45 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.44%
Tags
conferences
Stock TXG logo
10x Genomics Inc

Nasdaq:TXG

TXG Rankings

#1478 Ranked by Market Cap
#596 Ranked by Stock Gains
N/A Ranked by Dividends

TXG Stock Data

4.12B
102.65M
2.38%
92.4%
7.15%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
US
Pleasanton

About TXG

advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.